These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Wong SL; Faries MB; Kennedy EB; Agarwala SS; Akhurst TJ; Ariyan C; Balch CM; Berman BS; Cochran A; Delman KA; Gorman M; Kirkwood JM; Moncrieff MD; Zager JS; Lyman GH J Clin Oncol; 2018 Feb; 36(4):399-413. PubMed ID: 29232171 [TBL] [Abstract][Full Text] [Related]
44. Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes. Kunte C; Geimer T; Baumert J; Konz B; Volkenandt M; Flaig M; Ruzicka T; Berking C; Schmid-Wendtner MH J Am Acad Dermatol; 2011 Apr; 64(4):655-62; quiz 637. PubMed ID: 21315477 [TBL] [Abstract][Full Text] [Related]
45. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039 [TBL] [Abstract][Full Text] [Related]
46. [Prognosis after sentinel node biopsy in malignant melanoma]. Lock-Andersen J; Horn J; Sjøstrand H Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370 [TBL] [Abstract][Full Text] [Related]
47. Completion Lymph Node Dissection Based on Risk of Nonsentinel Metastasis in Cutaneous Melanoma of the Head and Neck. Fritsch VA; Cunningham JE; Lentsch EJ Otolaryngol Head Neck Surg; 2016 Jan; 154(1):94-103. PubMed ID: 26399717 [TBL] [Abstract][Full Text] [Related]
48. Lymphatic mapping and sentinel lymph node biopsy in the management of primary cutaneous melanoma: report of a single-centre experience. Cecchi R; De Gaudio C; Buralli L; Innocenti S Tumori; 2006; 92(2):113-7. PubMed ID: 16724689 [TBL] [Abstract][Full Text] [Related]
49. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. van der Ploeg AP; van Akkooi AC; Schmitz PI; Koljenovic S; Verhoef C; Eggermont AM Eur J Cancer; 2010 Sep; 46(13):2414-21. PubMed ID: 20621467 [TBL] [Abstract][Full Text] [Related]
50. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. Sabel MS; Griffith K; Sondak VK; Lowe L; Schwartz JL; Cimmino VM; Chang AE; Rees RS; Bradford CR; Johnson TM J Am Coll Surg; 2005 Jul; 201(1):37-47. PubMed ID: 15978442 [TBL] [Abstract][Full Text] [Related]
51. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma]. Keijzer R; Bril H; van der Loo EM; de Graaf PW Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391 [TBL] [Abstract][Full Text] [Related]
52. When should pelvic sentinel lymph nodes be harvested in patients with malignant melanoma? Kaoutzanis C; Barabás A; Allan R; Hussain M; Powell B J Plast Reconstr Aesthet Surg; 2012 Jan; 65(1):85-90. PubMed ID: 21940229 [TBL] [Abstract][Full Text] [Related]
53. Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma. Bagaria SP; Ray PS; Joseph RW; Heckman MG; Rawal B; Gray RJ; Pockaj B; Wasif N Cancer; 2013 May; 119(10):1860-7. PubMed ID: 23408288 [TBL] [Abstract][Full Text] [Related]
54. Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival. Oude Ophuis CM; van Akkooi AC; Rutkowski P; Voit CA; Stepniak J; Erler NS; Eggermont AM; Wouters MW; Grünhagen DJ; Verhoef CK Eur J Cancer; 2016 Nov; 67():164-173. PubMed ID: 27669503 [TBL] [Abstract][Full Text] [Related]
55. Molecular detection of sentinel node micrometastases in patients with clinical N0 gastric carcinoma with real-time multiplex reverse transcription-polymerase chain reaction assay. Shimizu Y; Takeuchi H; Sakakura Y; Saikawa Y; Nakahara T; Mukai M; Kitajima M; Kitagawa Y Ann Surg Oncol; 2012 Feb; 19(2):469-77. PubMed ID: 22065193 [TBL] [Abstract][Full Text] [Related]
56. Surgical management of tumor-positive interval node in melanoma patients: An observational study. Nacchiero E; Vestita M; Robusto F; Maruccia M; Annoscia P; Giudice G Medicine (Baltimore); 2018 May; 97(18):e0584. PubMed ID: 29718857 [TBL] [Abstract][Full Text] [Related]
57. The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients. Matter M; Nicod Lalonde M; Allaoua M; Boubaker A; Liénard D; Gugerli O; Cerottini JP; Bouzourene H; Bischof Delaloye A; Lejeune F J Nucl Med; 2007 Oct; 48(10):1607-13. PubMed ID: 17873127 [TBL] [Abstract][Full Text] [Related]
58. Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. Glumac N; Hocevar M; Zadnik V; Snoj M J Surg Oncol; 2008 Jul; 98(1):46-8. PubMed ID: 18452214 [TBL] [Abstract][Full Text] [Related]
59. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144 [TBL] [Abstract][Full Text] [Related]
60. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Mraz-Gernhard S; Sagebiel RW; Kashani-Sabet M; Miller JR; Leong SP Arch Dermatol; 1998 Aug; 134(8):983-7. PubMed ID: 9722728 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]